Oncology (all articles)
Review: Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer
30 Apr, 2021 | 08:31h | UTC
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage
29 Apr, 2021 | 08:28h | UTC
ASCO Guideline: Management of Salivary Gland Malignancy
28 Apr, 2021 | 08:13h | UTCManagement of Salivary Gland Malignancy: ASCO Guideline – Journal of Clinical Oncology
M-A: Helicobacter pylori eradication therapy to prevent gastric cancer – H. pylori eradication may reduce the incidence of gastric cancer in healthy individuals in East Asian countries
27 Apr, 2021 | 09:21h | UTCHelicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis (link to abstract – $ for full-text – free article here)
Guide to Enhanced Recovery for Cancer Patients Undergoing Liver Surgery
25 Apr, 2021 | 20:53h | UTCSee also: Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations – World Journal of Surgery AND Enhanced Recovery After Surgery (ERAS) Society Guidelines
RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer
25 Apr, 2021 | 20:57h | UTC
RCT: Treatments for vulnerable older adult women with ovarian cancer compared
23 Apr, 2021 | 08:15h | UTCEfficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)
Systematic review: Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
23 Apr, 2021 | 08:17h | UTC
Systematic Review: PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
23 Apr, 2021 | 08:16h | UTCSummary: PARP inhibitors for locally advanced or metastatic breast cancer – Cochrane Library
Survey: Despite guideline recommendations, many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone
23 Apr, 2021 | 08:13h | UTCTSH Suppression for Papillary Thyroid Cancer: A Physician Survey Study – Thyroid (link to abstract – $ for full-text)
Commentary on Twitter
Hot off the press. We found that many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone, emphasizing the need for more research to better guide thyroid cancer management. @AmThyroidAssn @UMRogelCancer https://t.co/iU3ObzQxBQ
— Maria Papaleontiou, MD (@MariaPapaleont1) March 30, 2021
Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared
22 Apr, 2021 | 08:24h | UTCRelated: Opinion – The high price of anticancer drugs: origins, implications, barriers, solutions AND Tackling the High Cost of Cancer Care AND Study: Clinician Engagement Regarding Financial Toxicity After Diagnosis of Cancer AND
RCT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
22 Apr, 2021 | 08:15h | UTCSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Guidelines for Management of Patients with Anaplastic Thyroid Cancer
20 Apr, 2021 | 05:24h | UTCCommentary: ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer – HealthDay
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
18 Apr, 2021 | 21:16h | UTC
M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy
18 Apr, 2021 | 21:14h | UTC
RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy
18 Apr, 2021 | 21:11h | UTCRobotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01)https://t.co/YenifaBnfe@doguteber @Hohenfellner pic.twitter.com/kfpQc1u0xf
— European Urology (@EUplatinum) February 11, 2021
RCT: An Enhanced Recovery After Surgery (ERAS) program in laparoscopic distal gastrectomy provided a faster recovery, a shorter postoperative hospitalization length, and lower medical costs without increasing complication and readmission rates
16 Apr, 2021 | 06:16h | UTCRelated: Consensus guidelines for enhanced recovery after gastrectomy – British Journal of Surgery AND Current status of the “enhanced recovery after surgery” program in gastric cancer surgery – Annals of Gastroenterological Surgery
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer
15 Apr, 2021 | 06:29h | UTC
Commentary on Twitter
What is the best treatment in locally advanced HN Cancer?
Our latest individual patient data network meta-analysis available here for free @TheLancetOncol: https://t.co/UuFvjpKO6I
Many limitations but by far the largest work on the topic (115 RCT, 29000 pts).
#radonc #hncsm pic.twitter.com/eNYHbxsB4Q
— Pierre Blanchard, MD (@PBlanchardMD) April 14, 2021
Review: Endocrine complications of immunotherapies
15 Apr, 2021 | 06:13h | UTCEndocrine complications of immunotherapies: a review – Clinical Medicine Journal
RCT: Low-dose aspirin safely suppresses the recurrence of colorectal polyps in patients with familial adenomatous polyposis
14 Apr, 2021 | 01:49h | UTCChemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Ishikawa et al – Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a randomised, 2×2 factorial trialhttps://t.co/NJ4b77p591#gitwitter #FAP #crcsm
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 2, 2021
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
14 Apr, 2021 | 01:27h | UTC
Perspective: Special diets might boost the power of drugs to vanquish cancers
8 Apr, 2021 | 08:43h | UTCSpecial diets might boost the power of drugs to vanquish cancers – Science
Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation
9 Apr, 2021 | 03:09h | UTCCancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation – JCO Global Oncology
RCT: Celecoxib for 3 years added to standard adjuvant therapy does not improve disease-free survival among patients with stage III colon cancer
7 Apr, 2021 | 01:28h | UTCEffect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Celecoxib for Stage III Colon Cancer – JAMA (free for a limited period)